STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADPT
  4. [144] Adaptive Biotechnologies Corp SEC Filing

Adaptive Biotech (NASDAQ: ADPT) director lines up $249,990 stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (symbol ADPT) received a Rule 144 notice from director Katherine E. Owen covering a planned sale of up to 9,615 shares of common stock. The shares are associated with restricted stock awards granted in 2022, 2023, and 2025 and are to be sold through Morgan Stanley Smith Barney LLC. The filing reports an aggregate market value of approximately $249,990 for the shares, with an approximate sale date of August 26, 2026 on NASDAQ.

Positive

  • None.

Negative

  • None.
Shares to be sold 9,615 shares of common stock Maximum number of Adaptive Biotechnologies shares covered by the Rule 144 notice
Aggregate market value $249,990.00 Aggregate market value of the 9,615 shares covered by the planned sale
Restricted stock grant 03/17/2022 1,110 shares Common stock underlying a restricted stock award dated March 17, 2022
Restricted stock grant 01/26/2023 6,689 shares Common stock underlying a restricted stock award dated January 26, 2023
Restricted stock grant 03/04/2025 1,816 shares Common stock underlying a restricted stock award dated March 4, 2025
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock financial
"Common | 03/17/2022 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC ... | 9615 | 249990.00"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing disclose for ADPT?
It discloses that director Katherine E. Owen has filed a Rule 144 notice for the potential sale of up to 9,615 shares of Adaptive Biotechnologies common stock, with an aggregate market value of about $249,990, to be sold through Morgan Stanley Smith Barney LLC.

How many ADPT shares are covered by Katherine Owen’s planned Rule 144 sale?
The notice covers up to 9,615 shares of Adaptive Biotechnologies common stock, tied to three restricted stock awards granted in 2022, 2023, and 2025.

What is the aggregate market value of the ADPT shares in this Form 144?
The filing states an aggregate market value of approximately $249,990 for the 9,615 Adaptive Biotechnologies shares covered by the planned sale.

When are the ADPT shares expected to be sold under this Form 144?
The approximate sale date reported is August 26, 2026, which is when the 9,615 shares of Adaptive Biotechnologies common stock may be sold on NASDAQ under Rule 144.

What types of ADPT securities are involved in Katherine Owen’s Form 144?
The securities are common stock of Adaptive Biotechnologies issued as restricted stock from grants dated March 17, 2022, January 26, 2023, and March 4, 2025.

Which broker is handling the planned ADPT Rule 144 sale?
The planned sale of Adaptive Biotechnologies shares is listed as being handled by Morgan Stanley Smith Barney LLC Executive Financial Services at One New York Plaza, New York.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR